[go: up one dir, main page]

NO20092306L - Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere - Google Patents

Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere

Info

Publication number
NO20092306L
NO20092306L NO20092306A NO20092306A NO20092306L NO 20092306 L NO20092306 L NO 20092306L NO 20092306 A NO20092306 A NO 20092306A NO 20092306 A NO20092306 A NO 20092306A NO 20092306 L NO20092306 L NO 20092306L
Authority
NO
Norway
Prior art keywords
compounds
interactions
methods
binding partners
bcl proteins
Prior art date
Application number
NO20092306A
Other languages
English (en)
Inventor
Alfredo C Castro
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Thomas T Tibbitts
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of NO20092306L publication Critical patent/NO20092306L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et aspekt av den foreliggende oppfinnelsen er relatert til heterosykliske forbindelser som binder til Bel proteiner og inhiberer Bel funksjon. Et annet aspekt av den foreliggende oppfinnelse er relatert til sammensetninger omfattende et heterosyklisk forbindelse av oppfinnelsen. Den foreliggende oppfinnelse tilveiebringer fremgangsmåter og behandling og modulering av lidelser assosiert med hyperproliferasjon, slik som cancer.
NO20092306A 2006-11-15 2009-06-15 Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere NO20092306L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PCT/US2007/023941 WO2008060569A1 (en) 2006-11-15 2007-11-14 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Publications (1)

Publication Number Publication Date
NO20092306L true NO20092306L (no) 2009-08-17

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092306A NO20092306L (no) 2006-11-15 2009-06-15 Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere

Country Status (20)

Country Link
US (2) US7842815B2 (no)
EP (1) EP2094673B1 (no)
JP (2) JP2010510214A (no)
KR (1) KR101530721B1 (no)
CN (1) CN101583606B (no)
AU (1) AU2007319848B2 (no)
BR (1) BRPI0718606A2 (no)
CA (1) CA2669596C (no)
EC (1) ECSP099398A (no)
ES (1) ES2537762T3 (no)
GT (1) GT200900123A (no)
IL (1) IL198597A (no)
MA (1) MA31067B1 (no)
MX (1) MX2009005184A (no)
MY (1) MY156754A (no)
NO (1) NO20092306L (no)
NZ (1) NZ577243A (no)
RU (1) RU2449996C2 (no)
TN (1) TN2009000182A1 (no)
WO (1) WO2008060569A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP2011511076A (ja) * 2008-02-08 2011-04-07 エイルロン セラピューティクス，インコーポレイテッド 治療用ペプチド模倣大環状分子
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
EP3367096B1 (en) 2012-02-06 2019-11-27 DiscoveRx Corporation Detection of intracellular binding events by measuring protein abundance
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
US20160068463A1 (en) 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
RU2716256C2 (ru) 2014-01-28 2020-03-11 Бак Инститьют Фо Ресеч Он Эйджинг Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
CA3018932C (en) 2016-03-28 2021-10-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
AU2018250147B2 (en) * 2017-04-05 2022-09-29 Eisai R&D Management Co., Ltd. Macrocyclic compound and uses thereof
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
WO2022008464A1 (en) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
HU222234B1 (hu) 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
ES2134870T3 (es) * 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
RU2149871C1 (ru) 1993-11-24 2000-05-27 Дзе Дюпон Мерк Фармасьютикал Компани Изоксазолины и изоксазолы, способ подавления агрегации тромбоцитов, фармацевтическая композиция, подавляющая агрегацию тромбоцитов
CA2185019C (en) 1994-03-09 2000-08-08 Pfizer Limited Isoxazoline compounds as inhibitors of tnf release
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
CA2262117A1 (en) 1996-08-16 1998-02-19 The Dupont Merck Pharmaceutical Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
WO1998050031A1 (en) 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
AU7105800A (en) 1999-09-01 2001-03-26 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
IL159110A0 (en) 2001-05-30 2004-06-01 Univ Michigan Small molecule antagonists of bcl2 family proteins
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
MXPA06014754A (es) 2004-06-17 2007-06-22 Infinity Pharmaceuticals Inc Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
US20060020004A1 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法

Also Published As

Publication number Publication date
CA2669596C (en) 2014-09-30
HK1130057A1 (en) 2009-12-18
IL198597A0 (en) 2010-02-17
RU2009121808A (ru) 2010-12-20
US20080306127A9 (en) 2008-12-11
MY156754A (en) 2016-03-31
KR20090082284A (ko) 2009-07-29
GT200900123A (es) 2011-09-02
WO2008060569A1 (en) 2008-05-22
BRPI0718606A2 (pt) 2013-12-17
CA2669596A1 (en) 2008-05-22
AU2007319848B2 (en) 2012-05-03
CN101583606A (zh) 2009-11-18
US7842815B2 (en) 2010-11-30
MX2009005184A (es) 2009-10-12
NZ577243A (en) 2011-12-22
US20110160259A1 (en) 2011-06-30
EP2094673B1 (en) 2015-04-08
RU2449996C2 (ru) 2012-05-10
TN2009000182A1 (en) 2010-10-18
JP2010510214A (ja) 2010-04-02
AU2007319848A1 (en) 2008-05-22
EP2094673A1 (en) 2009-09-02
ECSP099398A (es) 2009-07-31
KR101530721B1 (ko) 2015-06-22
US8461191B2 (en) 2013-06-11
CN101583606B (zh) 2015-04-08
MA31067B1 (fr) 2010-01-04
ES2537762T3 (es) 2015-06-11
IL198597A (en) 2014-03-31
JP2014055156A (ja) 2014-03-27
US20070161690A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
NO20092306L (no) Forbindelser og fremgangsmater for interaksjoner av BCL proteiner med binding partnere
NO20091213L (no) Forbindelser og fremgangsmater for a inhibere interaksjoner mellom BCL proteiner og bindingspartnere
NO20070324L (no) Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere
NO20083050L (no) Forbindelser og fremgangsmater for hemming av interaksjon av Bcl-proteiner med bindingspartnere
NO20092652L (no) Konstruert anti-TSLP-antistoff
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
NO20090624L (no) Forbindelser som modulerer CB2 receptoren
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
TW200640924A (en) VEGF-R2 inhibitors and methods
EA201790678A1 (ru) Бициклические гетероарильные соединения
IN2014MN02330A (no)
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
NO20061412L (no) Terapi av okulaere foretyrrelser
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
WO2007022947A3 (de) 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
DE602006020585D1 (de) Neue cysteinproteasehemmer und ihre therapeutische anwendung
MY155908A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TNSN06418A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
EA200702590A1 (ru) Ингибиторы растворимой аденилатциклазы

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application